SkinBioTherapeutics – France AxisBiotix-Ps regulatory approval, a commercialisation strategy continuing STRONG BUY
By HotStockRockets | Friday 22 September 2023
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
SkinBioTherapeutics (SBTX) has announced that it has received regulatory approval to sell its food supplement to alleviate the symptoms associated with psoriasis, AxisBiotix-Ps, into the French market and that marketing of the product there is expected to launch next month.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.